Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
University of Pennsylvania
Study ID
NCT05658913
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

  • AV-1451 — DRUG
    This is a cross-sectional study using the radiotracer AV-1451 to determine the relationship of tau pathology to other biomarker data of MPC participants.

Study Details

To collect Tau PET/CT imaging in older adults diagnosed with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) in the Mismatch Prospective Cohort Study (MPC-Tau) study to determine relationship to clinical, cognitive, and other biomarker data. Findings from this study will likely provide insight into the phenotypic variability of Alzheimer's Disease and other related pathologies.

Key Dates

Start date
Mar 14, 2023
Status verified
Aug 2025
Primary completion
Dec 31, 2027
Completion
Dec 31, 2029

Study Design

Enrollment
100 participants (estimated)

Primary Outcome Measure

Clusters based on spatial pattern and extent of T-N Mismatch [ Time Frame: 5 years ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Massachusetts General HospitalBostonMassachusetts02114-2696
Bradford Dickerson, MD
[email protected]
617-726-6205
Erin Krahn
[email protected]
617-726-6205
Bradford Dickerson, MD (PRINCIPAL_INVESTIGATOR)
University of PennsylvaniaPhiladelphiaPennsylvania19104
Jackie Lane
[email protected]
610-299-1243
David Wolk, MD (PRINCIPAL_INVESTIGATOR)
Sandhitsu Das, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By condition
Alzheimer's disease
By specialty
NeurologyDementia careBrain disordersGeriatrics
By research site
Massachusetts General Hospital· Boston, MAUniversity of Pennsylvania· Philadelphia, PA

Related Studies